贝那普利联合比索洛尔治疗慢性充血性心力衰竭患者的临床疗效评价

Clinical evaluation of benazepril combined with bisoprolol in the treatment of chronic congestive heart failure

目的评价贝那普利联合比索洛尔治疗慢性充血性心力衰竭患者的临床疗效。方法选择2018年3月至2020年6月在本院进行治疗的慢性充血性心力衰竭患者126例,随机分为对照组和研究组各63例。两组患者均给予利尿、强心、扩张血管和吸氧等常规对症治疗,同时予以饮食干预和运动干预。对照组在常规治疗基础上口服贝那普利,研究组在对照组基础上加用比索洛尔。比较两组患者的心功能指标和神经内分泌指标变化、临床疗效,并采用日常生活活动表(ADL)对两组患者治疗前后的日常生活能力进行评分。结果治疗后,两组患者的心功能指标及神经内分泌指标均较治疗前有所改善,研究组的LVEF高于对照组,LVEDD、LVESD以及各神经内分泌指标均低于对照组,研究组有效率以及ADL评分均高于对照组,差异有统计学意义(P<0.05)。结论贝那普利联合比索洛尔治疗慢性充血性心力衰竭的临床疗效显著,能够有效改善患者心功能,降低神经内分泌水平,且安全性高,值得临床应用和推广。

Objective To evaluate the clinical efficacy of benazepril combined with bisoprolol in the treatment of patients with chronic congestive heart failure. Methods A total of 126 patients with chronic congestive heart failure treated in our hospital from March 2018 to June 2020 were selected as the research subjects, and they were divided into control group and study group randomly, with 63 cases in each group. Patients in both groups were given conventional symptomatic treatment, such as diuretic, cardiac, vasodilation and oxygen inhalation, as well as diet intervention and exercise intervention. The control group was given benazepril orally on the basis of conventional treatment, while the study group was given bisoprolol additionally on the basis of control group. The changes of cardiac function indexes and neuroendocrine indexes, as well as clinical efficacy were compared between the two groups. Activity of daily living(ADL) was used to compare the ability of daily living of the two groups before and after treatment. Results Cardiac function indexes and neuroendocrine indexes in the two groups improved compared with those before treatment, LVEF in the study group was higher than that in the control group, LVEDD, LVESD and various neuroendocrine indexes were lower than those in the control group, and the effective rate and ADL score after treatment were higher than those in the control group, with statistical significance(P<0.05). Conclusion Benazapril combined with bisoprolol has significant clinical efficacy in the treatment of chronic congestive heart failure, which can effectively improve cardiac function, reduce neuroendocrine level, with high safety, and is worthy of clinical application and promotion.